The global 22q11.2 deletion syndrome therapeutics market is experiencing a period of significant growth, driven by factors such as increasing recognition of the condition and the development of novel therapeutic interventions. Scientists are actively pursuing a broad range of therapeutic avenues, including gene therapy, chemical therapies, and cell